Quisel John D 4

What Happened

• John D. Quisel, Chief Executive Officer of Disc Medicine (IRON), exercised a total of 33,000 option shares (25,584 at $9.86 and 7,416 at $13.50) on July 13, 2026 (exercise cost $352,374) and sold 33,000 shares in open‑market transactions that day for aggregate gross proceeds of about $2,473,780. The transactions were effected under a Rule 10b5‑1 trading plan.

Key Details

• Transaction date: July 13, 2026; Form 4 filed July 14, 2026 (timely).
• Options exercised: 25,584 shares @ $9.86 = $252,258; 7,416 shares @ $13.50 = $100,116 (total exercise cost $352,374).
• Shares sold (open market): 9,704 @ weighted avg $74.27 (range $73.62–$74.60); 16,896 @ weighted avg $74.95 (range $74.62–$75.50); 6,400 @ weighted avg $76.05 (range $75.83–$76.29). Total gross proceeds ≈ $2,473,780.
• Reporting mechanics: The filing shows both the exercise (acquisition) and disposition of derivative shares (zero‑dollar derivative disposition entries); the trades were conducted pursuant to a 10b5‑1 plan adopted March 12, 2026 (Footnote F1).
• Vesting notes: Footnotes indicate one option grant is fully vested (F5) and another vests in 48 equal monthly installments beginning Dec 29, 2022 (F6).
• Shares owned after the transactions: not specified in the provided excerpt of the filing.

Context

• This appears to be a cashless exercise / same‑day sale pattern: options were exercised and resulting shares were sold on the same day under a prearranged 10b5‑1 plan. Such transactions are commonly used to cover exercise costs and taxes and are not necessarily a forward-looking signal about the CEO’s view of the company.
• The sales generated significant gross proceeds ($2.47M) while the exercise cost was modest by comparison ($0.35M). The use of a 10b5‑1 plan indicates the trades were preplanned.